Skip to main content

Advertisement

Table 1 Demographic, clinical and urological features of the patients with MS

From: Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

  Ranges Totals Women Men p value
Sex, N (%)   109 (100.0) 80 (73.4) 29 (26.6)  
Age, mean ± SD 24 – 67 44,6 ± 10,1 43,8 ± 9,0 44,3 ± 10,5 NS
RRMS, N (%)   99 (90.8) 73 (53.4) 26 (89.6) NS
SPMS, N (%)   10 (9.2) 7 (8.7) 3 (10.3) NS
EDSS, mean ± SD 0.0 – 7.0 2,6 ± 1,7 2,5 ± 1,7 2,6 ± 1,8 NS
Disease duration (y), mean ± SD 0.9 – 43 12,5 ± 8,7 12,6 ± 8,8 11,3 ± 8,8 NS
Immunomodulatory treatment, N (%)   69 (63.3) 50 (62.5) 19 (65.5) NS
Immunosuppressive treatment, N (%)   6 (5.5) 5 (6.2) 1 (3.5) NS
Untreated, N (%)   34 (31.2) 25 (31.3) 9 (31.0) NS
Patients with ≥1 urinary symptom, N (%)   57 (52.3) 39 (48.7) 18 (62.1) NS
 1 symptom   38 (65.5) 24 (61.5) 14 (77.7) NS
 2 symptoms   15 (25.9) 11 (27.5) 4 (22.2) NS
  ≥ 3 symptoms   5 (8.6) 5 (12.5) 0 (0.0) NS
 Urgency   44 (40.4) 32 (40.0) 12 (41.2) NS
 Frequency   17 (15.6) 13 (16.2) 4 (13.8) NS
 Incomplete emptying   13 (11.9) 10 (12.5) 3 (10.3) NS
 Hesitancy   9 (8.3) 8 (10.0) 1 (5.5) NS
 Urge incontinence   3 (3.7) 3 (3.7) 1 (3.5) NS
Qmax, mean ± SD 0 – 65 19.8 ± 11.2 21.1 ± 11.3 17.0 ± 7.1 0.029
Abnormal values (<15 ml/s), N (%)   38 (34.9) 26 (32.5) 12 (41.4) NS
PVR, mean ± SD 0 – 1000 66.6 ± 82.1 64.6 ± 85.1 73.6 ± 75.1 NS
Abnormal values (<15 ml/s), N (%)   44 (40.4) 28 (35.0) 16 (55.2) NS
DSD, N (%)   37 (33.9) 32 (40.0) 5 (17.2) 0.016
  1. Abbreviations: RRMS Relapsing-Remitting Multiple Sclerosis, SPMS Secondary Progressive Multiple Sclerosis, EDSS Expanded Disability Status Scale, Qmax maximum urinary flow rate, PVR postvoid residual urine volume, DSD detrusor sphincter dyssinergia